Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a) What would you do in such a situation? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?

Facts in brief

Under pressure to win first-mover advantage during an outbreak, Dr. Srinivasan's team suggests manipulating trial data, hiding negative outcomes, skipping informed consent and using a rival's patented compound. He is uncomfortable but fears missing targets.

Stakeholders

• Patients and the public (safety, right to a genuinely effective drug)
• Dr. Srinivasan (professional integrity, career)
• The company (profit, reputation, legal risk)
• Trial participants (informed consent, dignity)
• The rival firm (intellectual property)

Ethical issues

• Scientific fraud: data manipulation and selective reporting endanger lives
• Violation of informed consent and human-subject dignity
• Intellectual-property theft (using patented compounds)
• Conflict between commercial pressure and research integrity and public safety

(a) What I would do

I would firmly refuse every shortcut, uphold rigorous, honest trials and informed consent, and escalate to management and the ethics/institutional review board. I would seek realistic timelines, added resources, and, if needed, licensing rather than stealing IP.

(b) Options and consequences

• Cut corners: short-term speed, but risks unsafe drugs, deaths, litigation, bans and ruined reputation.
• Refuse and do it right: slower, possible loss of first-mover edge, but safe, credible, legally sound outcomes and lasting trust.

(c) How data and drug ethics save humanity

Honest data ensures a drug's benefits and risks are truly known, preventing mass harm; drug ethics — safety, efficacy, consent — protects patients and public trust in medicine. Ethical rigor, not speed, is what ultimately safeguards humanity, as thalidomide-era reforms taught the world.